NEWS

You may access the full Serina Therapeutics' news archive here,  and also see upcoming events where you can meet with the Serina team.

Newspaper Icon

ALL PRESS RELEASES

February 14, 2017 Serina Therapeutics Announces Completion of Enrollment in the Phase Ia Trial of SER-214 in Parkinson’s Disease
January 26, 2017 Serina Therapeutics Announces Appointment of Mr. Mike Loya to Serina’s Board of Directors
January 3, 2017 Serina Therapeutics Announces President and CEO will Speak at the Upcoming BIO CEO and Investor Conference in New York February 13
October 18, 2016 Serina Therapeutics Announces Publication of Invited Feature Article in European Polymer Journal
September 12, 2016 Announces Speaking at CNS Diseases World Summit 2016
August 22, 2016 Serina Therapeutics Announces President and CEO will Deliver Invited Lecture on POZ Therapeutics at Annual American Chemical Society Meeting in Philadelphia
June 6, 2016 Serina Therapeutics Announces Advancing to Multi-Dose Phase in Parkinson’s Disease Patients in the SER-214 Phase I Trial
May 16, 2016 Serina Therapeutics Announces Appointment of Dr. Brendan Rae as CBO
January 19, 2016 Serina Therapeutics Announces Dosing of First Patient in SER-214 Phase I Study
July 1, 2015 Serina Therapeutics Announces Filing of Investigational New Drug (IND) Application for SER-214 for the Treatment of Parkinson’s Disease
June 2, 2015 Serina Therapeutics Announces Follow-on Agreement with AstraZeneca for Development of a Proprietary POZ-therapeutic
December 18, 2014 Serina Therapeutics Announces Close of $ 5 Million Financing to Advance SER-214 and Polymer Oncology Programs
August 8, 2014 Serina Therapeutics to Co-Sponsor Session on Poly(2-oxazoline)s and Polypeptoids at American Chemical Society in San Francisco August 10-12th 2014
April 21, 2014 Serina Therapeutics’ CEO Selected as Panelist at 2014 Neurotech Investing and Partnering Conference
March 17, 2014 Serina Therapeutics’ CEO Will Lead Session on Biorelated Polymers at the 12th International Symposium of the American Chemical Society
March 6, 2014 Serina Therapeutics Announces Issuance of Key Patents in China and Europe Extending the POZ Patent Estate Globally
October 30, 2013 Serina Therapeutics Announces Publication of SER-214 (POZ-Rotigotine) Article in Journal of Movement Disorders
July 31, 2013 Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
April 17, 2013 Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
April 4, 2013 Serina Therapeutics Announces Exclusive License Agreement with The Scripps Research Institute for ‘Click Chemistry’
March 25, 2013 US Patent and Trademark Office awards Serina Therapeutics key patent covering its lead clinical candidate for Parkinson’s Disease and Restless Leg Syndrome
January 16, 2013 Serina Therapeutics announces agreement with AstraZeneca for development of a polyoxazoline (POZ) therapeutic
December 18, 2012 Serina Therapeutics, Inc. President and CEO interviewed by Life Science Leader magazine and Serina is highlighted as “Company to Watch” in 2013
October 9, 2012 Serina Therapeutics President and CEO Randall Moreadith, MD, PhD to present at annual BIO Investor Forum in San Francisco
June 18, 2012 Serina Therapeutics to present novel Parkinson’s disease treatment
March 26, 2012 Serina Therapeutics co-sponsors symposium on polyoxazoline chemistry
March 1, 2012 Serina Therapeutics awarded multiple patents for its polymer drug delivery technology
June 1, 2011 Serina Therapeutics, Inc. Closes $ 9.5 Million Financing Round
May 17, 2011 Serina Therapeutics awarded patent for its core polymer drug delivery technology
Newspaper Icon

PRESS RELEASES 2017

January 3, 2017 Serina Therapeutics Announces President and CEO will Speak at the Upcoming BIO CEO and Investor Conference in New York February 13
January 26, 2017 Serina Therapeutics Announces Appointment of Mr. Mike Loya to Serina’s Board of Directors
February 14, 2017 Serina Therapeutics Announces Completion of Enrollment in the Phase Ia Trial of SER-214 in Parkinson’s Disease
Newspaper Icon

PRESS RELEASES 2016

January 19, 2016 Serina Therapeutics Announces Dosing of First Patient in SER-214 Phase I Study
May 16, 2016 Serina Therapeutics Announces Appointment of Dr. Brendan Rae as CBO
June 6, 2016 Serina Therapeutics Announces Advancing to Multi-Dose Phase in Parkinson’s Disease Patients in the SER-214 Phase I Trial
August 22, 2016 Serina Therapeutics Announces President and CEO will Deliver Invited Lecture on POZ Therapeutics at Annual American Chemical Society Meeting in Philadelphia
September 12, 2016 Announces Speaking at CNS Diseases World Summit 2016
October 18, 2016 Serina Therapeutics Announces Publication of Invited Feature Article in European Polymer Journal
Newspaper Icon

PRESS RELEASES 2015

June 2, 2015 Serina Therapeutics Announces Follow-on Agreement with AstraZeneca for Development of a Proprietary POZ-therapeutic
July 1, 2015 Serina Therapeutics Announces Filing of Investigational New Drug (IND) Application for SER-214 for the Treatment of Parkinson’s Disease
Newspaper Icon

PRESS RELEASES 2014

March 6, 2014 Serina Therapeutics Announces Issuance of Key Patents in China and Europe Extending the POZ Patent Estate Globally
March 17, 2014 Serina Therapeutics’ CEO Will Lead Session on Biorelated Polymers at the 12th International Symposium of the American Chemical Society
April 21, 2014 Serina Therapeutics’ CEO Selected as Panelist at 2014 Neurotech Investing and Partnering Conference
August 8, 2014 Serina Therapeutics to Co-Sponsor Session on Poly(2-oxazoline)s and Polypeptoids at American Chemical Society in San Francisco August 10-12th 2014
December 18, 2014 Serina Therapeutics Announces Close of $ 5 Million Financing to Advance SER-214 and Polymer Oncology Programs
Newspaper Icon

PRESS RELEASES 2013

January 16, 2013 Serina Therapeutics announces agreement with AstraZeneca for development of a polyoxazoline (POZ) therapeutic
March 25, 2013 US Patent and Trademark Office awards Serina Therapeutics key patent covering its lead clinical candidate for Parkinson’s Disease and Restless Leg Syndrome
April 4, 2013 Serina Therapeutics Announces Exclusive License Agreement with The Scripps Research Institute for ‘Click Chemistry’
April 17, 2013 Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
July 31, 2013 Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
October 30, 2013 Serina Therapeutics Announces Publication of SER-214 (POZ-Rotigotine) Article in Journal of Movement Disorders
Newspaper Icon

PRESS RELEASES 2012

March 1, 2012 Serina Therapeutics awarded multiple patents for its polymer drug delivery technology
March 26, 2012 Serina Therapeutics co-sponsors symposium on polyoxazoline chemistry
June 18, 2012 Serina Therapeutics to present novel Parkinson’s disease treatment
October 9, 2012 Serina Therapeutics President and CEO Randall Moreadith, MD, PhD to present at annual BIO Investor Forum in San Francisco
December 18, 2012 Serina Therapeutics, Inc. President and CEO interviewed by Life Science Leader magazine and Serina is highlighted as “Company to Watch” in 2013
Newspaper Icon

PRESS RELEASES 2011

May 17, 2011 Serina Therapeutics awarded patent for its core polymer drug delivery technology
June 1, 2011 Serina Therapeutics, Inc. Closes $ 9.5 Million Financing Round

MEETINGS & EVENTS

Calendar Icon

February 13-14, 2017

Waldorf Astoria

New York City, NY

BIO CEO and Investor Conference

Calendar Icon

June 19-22, 2017

San Diego, CA

BIO - Biotechnology Industry Organization 2017